Cardiovascular function and prognosis of patients with heart failure coexistent with chronic obstructive pulmonary disease

Abstract Background Chronic obstructive pulmonary disease (COPD) often coexists with heart failure (HF), and is considered to be associated with adverse outcomes in HF patients. However, the features of cardiovascular function and the detailed all-cause mortality of HF with COPD remain unclear. Meth...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiology 2014-10, Vol.64 (4), p.256-264
Hauptverfasser: Yoshihisa, Akiomi, MD, PhD, Takiguchi, Mai, MD, Shimizu, Takeshi, MD, Nakamura, Yuichi, MD, Yamauchi, Hiroyuki, MD, Iwaya, Shoji, MD, Owada, Takashi, MD, Miyata, Makiko, MD, Abe, Satoshi, MD, Sato, Takamasa, MD, Suzuki, Satoshi, MD, PhD, Oikawa, Masayoshi, MD, PhD, Kobayashi, Atsushi, MD, PhD, Yamaki, Takayoshi, MD, PhD, Sugimoto, Koichi, MD, PhD, Kunii, Hiroyuki, MD, PhD, Nakazato, Kazuhiko, MD, PhD, Suzuki, Hitoshi, MD, PhD, Saitoh, Shu-ichi, MD, PhD, Takeishi, Yasuchika, MD, PhD, FJCC
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Chronic obstructive pulmonary disease (COPD) often coexists with heart failure (HF), and is considered to be associated with adverse outcomes in HF patients. However, the features of cardiovascular function and the detailed all-cause mortality of HF with COPD remain unclear. Methods and results Consecutive 378 patients admitted for HF who underwent spirometry were divided into three groups: HF without COPD (non-COPD group, n = 272), HF with mild COPD (GOLD I group, n = 82), and HF with moderate COPD (GOLD II group, n = 24). The GOLD II group, as compared to non-COPD group, had (1) higher troponin T ( p = 0.009); (2) greater cardio-ankle vascular index ( p = 0.032); and (3) similar cardiac systolic and diastolic function of the right and left ventricle. In addition, rates of cardiac ( p = 0.049), non-cardiac ( p = 0.001), and all-cause mortality ( p = 0.002) were higher in GOLD II group than in non-COPD and GOLD I groups. Importantly, in the Cox proportional hazard analyses, the GOLD stage II was an independent predictor of cardiac ( p = 0.038), non-cardiac ( p = 0.036), and all-cause mortality ( p = 0.015) in HF patients. Conclusions HF patients with coexistent moderate COPD (GOLD stage II) have greater myocardial damage, greater arterial stiffness, and higher cardiac and non-cardiac mortality.
ISSN:0914-5087
1876-4738
DOI:10.1016/j.jjcc.2014.02.003